Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXGet Rating) in a research report sent to investors on Friday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.0 %

Shares of BTX opened at $0.21 on Friday. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brooklyn ImmunoTherapeutics stock. Lake Street Advisors Group LLC purchased a new stake in Brooklyn ImmunoTherapeutics Inc (NYSE:BTXGet Rating) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,446,417 shares of the company’s stock, valued at approximately $604,000. Lake Street Advisors Group LLC owned approximately 4.16% of Brooklyn ImmunoTherapeutics as of its most recent SEC filing.

About Brooklyn ImmunoTherapeutics

(Get Rating)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Read More

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with's FREE daily email newsletter.